Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Fish and Richardson
Argus Health
US Department of Justice
QuintilesIMS
Cantor Fitzgerald
Federal Trade Commission
Chinese Patent Office
Queensland Health

Generated: May 23, 2018

DrugPatentWatch Database Preview

TRAVATAN Z Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Travatan Z patents expire, and when can generic versions of Travatan Z launch?

Travatan Z is a drug marketed by Novartis Pharms Corp and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has forty-three patent family members in twenty-two countries.

The generic ingredient in TRAVATAN Z is travoprost. There are fourteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the travoprost profile page.
Drug patent expirations by year for TRAVATAN Z
Pharmacology for TRAVATAN Z
Ingredient-typeProstaglandins
Drug ClassProstaglandin Analog
Medical Subject Heading (MeSH) Categories for TRAVATAN Z
Synonyms for TRAVATAN Z
(((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester
(+)-Fluprostenol isopropyl ester
(1R-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-Dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester
(5Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-buten-1-yl]cyclopentyl]-5-heptenoic acid 1-methyethyl ester
(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3R)-3-hydroxy-4-((alpha,alpha,alpha-trifluoro-m-isopropyl-tolyl)oxy)-1-butenyl)cyclopentyl)-5-heptenoate
(Z)-isopropyl 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R,E)-3-hydroxy-4-(3-(trifluoromethyl) phenoxy)but-1-en-1-yl)cyclopentyl)hept-5-enoate
(Z)-isopropyl 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R,E)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-en-1-yl)cyclopentyl)hept-5-enoate
(Z)-isopropyl 7-((1R,2R)-3,5-dihydroxy-2-((S,E)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-en-1-yl)cyclopentyl)hept-5-enoate
157283-68-6
207742-69-6
283T686
5-Heptenoic acid, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-, 1-methylethyl ester, (5Z)-
5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-, 1-methylethyl ester, (1R-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-
5-Heptenoic acid,7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-,1-methylethyl ester,(5Z)
AB2000145
AC-6103
AC1NQZOS
AKOS024458039
AL-6221
AL6221
AM84515
AN-10392
C26H35F3O6
CHEBI:746859
CHEMBL1200799
CS-2773
D01964
D09CZA
DB00287
Fluprostenol isopropyl ester
Fluprostenol isopropyl ester, >=98%, ethanol solution
GTPL7102
HY-B0584
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R,E)-3-hydroxy-4-(3-(trifluoromethyl)-phenoxy)-but-1-enyl)-cyclopentyl)-hept-5-enoate
isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R,E)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-en-1-yl)cyclopentyl)hept-5-enoate
isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate
Izba
J-502633
LP015610
LS-173521
M978
MKPLKVHSHYCHOC-AHTXBMBWSA-N
MolPort-006-167-507
propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl]cyclopentyl]hept-5-enoate
propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl}cyclopentyl]hept-5-enoate
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate
RP17770
SC-50922
SCHEMBL93818
SR-01000942266
SR-01000942266-1
SR-01000946860
SR-01000946860-1
Travaprost
Travatan
Travatan (TN)
Travatan Alcon
Travatan Z (TN)
Travatan, Travoprost
Travatanz
Travoprost
Travoprost (JAN/USAN/INN)
Travoprost [USAN:USP:INN:BAN]
Travoprost [USAN]
travoprostum
UNII-WJ68R08KX9
WJ68R08KX9
Z6131
ZINC4474682

US Patents and Regulatory Information for TRAVATAN Z

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp TRAVATAN Z travoprost SOLUTION/DROPS;OPHTHALMIC 021994-001 Sep 21, 2006 AT RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Novartis Pharms Corp TRAVATAN Z travoprost SOLUTION/DROPS;OPHTHALMIC 021994-001 Sep 21, 2006 AT RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Novartis Pharms Corp TRAVATAN Z travoprost SOLUTION/DROPS;OPHTHALMIC 021994-001 Sep 21, 2006 AT RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for TRAVATAN Z

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp TRAVATAN Z travoprost SOLUTION/DROPS;OPHTHALMIC 021994-001 Sep 21, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp TRAVATAN Z travoprost SOLUTION/DROPS;OPHTHALMIC 021994-001 Sep 21, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp TRAVATAN Z travoprost SOLUTION/DROPS;OPHTHALMIC 021994-001 Sep 21, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp TRAVATAN Z travoprost SOLUTION/DROPS;OPHTHALMIC 021994-001 Sep 21, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for TRAVATAN Z
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Ophthalmic Solution 0.00% ➤ Subscribe 2009-02-19

or, see our see our flat-rate plans

Supplementary Protection Certificates for TRAVATAN Z

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00540 Netherlands ➤ Try a Free Trial PRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EU/1/01/199/001-002 20011127
2014 00038 Denmark ➤ Try a Free Trial PRODUCT NAME: TRAVOPROST; REG. NO/DATE: EU/1/01/199/001-002 20011127
2012017,C1920764 Lithuania ➤ Try a Free Trial PRODUCT NAME: TRAVOPROSTUM; NAT. REGISTRATION NO/DATE: LT 02/7821/3 20020402; FIRST REGISTRATION: EU/1/01/199/001 - EU/1/01/199/002 20011127
2014029 Lithuania ➤ Try a Free Trial PRODUCT NAME: TRAVOPROSTUM; REGISTRATION NO/DATE: EU/1/01/199/001 - EU/1/01/199/002 20011129
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Cantor Fitzgerald
McKinsey
Dow
US Department of Justice
Colorcon
QuintilesIMS
Covington
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.